ProCE Banner Activity

Los expertos responden a sus preguntas sobre los inhibidores de CDK4/6 en el cáncer de mama RH+/HER2-

PDF

Read this ClinicalThought Commentary translated in Spanish with answers from experts to healthcare professional questions from a recent live event focused on CDK4/6 inhibitors in HR-positive/HER2-negative breast cancer care. 

Released: August 21, 2024

Expiration: August 20, 2025

Share

Faculty

Sara A. Hurvitz

Sara A. Hurvitz, MD, FACP

Professor of Medicine
Head, Division of Hematology and Oncology
Department of Medicine, UW Medicine
Senior Vice President
Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington

Erica L. Mayer

Erica L. Mayer, MD, MPH

Director of Breast Cancer Clinical Research
Dana-Farber Cancer Institute
Associate Professor in Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation